Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
NEW YORK, May 01, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2018 financial results prior to market open on Tuesday, May 8, 2018. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. Eastern Time to discuss the results.
Intercept management will also be presenting at the following upcoming investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference at 9:20 a.m. ET on Wednesday, May 9, 2018
- Bank of America Merrill Lynch 2018 Healthcare Conference at 5:00 p.m. PT on Tuesday, May 15, 2018
- UBS Global Healthcare Conference at 3:00 p.m. ET on Monday, May 21, 2018
- Jefferies 2018 Global Healthcare Conference at 9:00 a.m. ET on Friday, June 8, 2018
Webcast information for these events will be available on the investor page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
CONTACT
For more information about Intercept Pharmaceuticals, please contact:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
